Wednesday, February 29th, 2012 at 8:27 PM
The Aviisha Medical Institute’s DriveSafe Program is lowering costs associated with the testing and treatment of sleep apnea for commercial drivers. Launched in February, the program is also aimed at raising awareness about this serious disease and helping drivers stay compliant.
The DriveSafe Program is the institute’s latest effort to combat the effects of sleep apnea. Sleep apnea has recently been spotlighted in the commercial driver industry.
In January, the Federal Motor Carrier Safety Administration (FMCSA) announced that it had adopted recommendations to have all commercial drivers with a body mass index of 35 or higher tested for sleep apnea. A person with a body mass index of 35 or higher is considered obese and is at high risk of having sleep apnea. Read the rest of this entry
Monday, February 20th, 2012 at 1:43 PM
NovaSom, Inc., the leader in obstructive sleep apnea (OSA) home testing and cost-containment solutions, has announced UnitedHealthcare plan participants now have access to NovaSom home sleep testing services for sleep apnea diagnosis. Home sleep testing is a clinically equivalent alternative to in-facility sleep testing that can be performed from the comfort and privacy of a patient’s home, at a fraction of the cost.
NovaSom will utilize its field-based provider relations team to educate physicians on appropriate screening parameters that will help identify clinically appropriate patients for home sleep testing. NovaSom will also make available a customized, provider-friendly workflow process aligned with prior authorization requirements to assure cost-effective diagnosis and initiation of treatment through its proprietary cloud-based MediTrack®System. Read the rest of this entry
Wednesday, January 25th, 2012 at 9:46 PM
Home sleep testing devices have become popular among medical providers to determine whether or not patients may have obstructive sleep apnea. Left untreated, sleep apnea can account for higher risks of accidents, obesity, heart disease, diabetes, and even colon cancer.
Medical professionals upload raw data off the machine through the pm-Assist? service that is scored by Registered Polysomnographic Technicians (RPSGT), interpreted by Board Certified Sleep Physicians, and in as little as 24 hours receive a diagnostic report.
“The growth of our pm-Assist program parallels the growth of home sleep testing in the industry,” commented Dr. Benjamin Gerson, Chief Medical Director of University Services, the parent company of pm-Assist. Read the rest of this entry
Thursday, January 19th, 2012 at 3:09 PM
As the number of patients diagnosed with sleep apnea is increasing the costs related to the health insurance is also increasing exponentially. This skyrocketing of the insurer’s sleep apnea related costs has now compelled the insurance companies to change their health coverage policies for the disorder.
A sleep apnea diagnosis usually requires patients undergo tests overnight in a sleep lab; some patients spend two nights in the lab to separately test for sleep apnea and to try a continuous positive airway pressure (CPAP) machine. Insurers often spend $1,900 for one overnight stay.
As a result of this increased spending, some experts are concerned that overnight tests to diagnose apnea are over-prescribed. Medicare payments for sleep testing increased from $62 million in 2001 to $235 million in 2009.
This contrasts effective home sleep tests that cost less than a fifth of the lab version. Although Medicare began paying for home sleep tests in 2008, the tests have had only modest growth. Read the rest of this entry
Wednesday, January 11th, 2012 at 3:42 PM
Verizon Wireless and NovaSom, Inc., the leader in obstructive sleep apnea (OSA) home testing, will be showcasing the NovaSom’s AccuSom Home Sleep Test at 2012 International Consumer Electronics Show (CES), [the Verizon booth ,Las Vegas Convention Center, South Hall, Booth #30259].
The AccuSom Home Sleep Test is used in the diagnosis of obstructive sleep apnea(OSA), one of the most serious and under-diagnosed medical conditions in the United States, affecting nearly 18 million Americans. AccuSom is the only FDA-cleared wireless home sleep test on the market, utilizing Verizon’s network to wirelessly collect and transfer sleep data from the patient’s home to a proprietary cloud-based sleep apnea management platform for physician interpretation and diagnosis. Read the rest of this entry
Tuesday, December 20th, 2011 at 3:21 PM
Reportlinker.com announces that a new market research report is available in its catalogue:
United States Anesthesia and Respiratory Devices Market Outlook to 2017 – Respiratory Devices, Respiratory Measurement Devices, Airway and Anesthesia Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
The report provides key market data on the United States Anesthesia and Respiratory Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within eight market categories – Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables, Respiratory Measurement Devices and Sleep Apnea Diagnostic Systems. Read the rest of this entry
Wednesday, December 14th, 2011 at 2:49 PM
The Motor Carrier Safety Advisory Committee and the Medical Review Board of the FMCSA held a joint public meeting in Alexandria, VA, to discuss guidance for medical examiners to identify commercial drivers with a high pre-test probability of having Obstructive Sleep Apnea, define conditional certification, and what constitutes immediate disqualification. “These recommendations are a step in the right direction,” commented Richard Thiel, Director of Making Sleep Work For You?, a nationwide sleep disorder program, “both entities recognize how OSA is an issue in the industry, and are taking steps to not only address it, but also give clear guidelines to all stakeholders involved.”
Subcommittees of each group working together will meet in January to draft more detailed recommendations to the FMCSA, and another joint meeting of these entities will take place in February 2012 to finalize the detailed recommendations. A public comment period will also be available before the FMCSA issues these recommendations as final guidance. Read the rest of this entry
Wednesday, November 30th, 2011 at 9:46 PM
NovaSom, Inc., the leader in obstructive sleep apnea (OSA) home testing and cost-containment solutions, announces the launch of its next generation MediTrack(R) cloud-based CRM application. The MediTrack OSA management platform is designed to enable custom processing of payer-specific medical policy, billing, utilization management and therapy coordination requirements to efficiently manage home sleep testing, OSA diagnosis and recommended therapy.
NovaSom’s proprietary MediTrack system allows physicians to order a NovaSom home sleep test online or by fax. The platform provides customizable information fields for easier physician entry of payer required data, leverages payer communication preferences, and incorporates payer-specific messaging into patient shipping and handling and device return logistics. The system also manages rapid upload of patient sleep data for interpretation by a Board Certified physician, and then promptly publishes the OSA study results for secure online and fax delivery to the ordering physician. Upon positive diagnosis, the MediTrack technology integrates assignment of payer-preferred therapy providers. Read the rest of this entry
Wednesday, November 9th, 2011 at 7:46 PM
The ResMed S9 is a uniquly designed sleep apnea device and only because of this the device ResMed S9 won a Red Dot design award last year.
Michael Farrell, senior vice president at ResMed’s global sleep strategic business unit, said: “Great design in medical devices should combine good looks, innovation and user-friendliness, as well as address an unmet medical need.”
The device uses special quality plastics in its manufacturing. This is called the ” Cycoloy polycarbonate/acrylonitrile-butadiene-styrene (PC/ABS) resin”.Sabic Innovative Plastics is the company that manufactures the “Lexan and Cycoloy materials” that have been used in the making of the award-winning ResMed S9 series of sleep apnea devices.
Sabic’s Cycoloy polycarbonate/acrylonitrile-butadiene-styrene (PC/ABS) resin is used to mould the complex, thin-wall S9 chassis. The high-flow material uses a non-halogenated flame retardant.
The tough Sabic Lexan polycarbonate is biocompatible and has a high-quality surface finish. It is used for the S9 top case and also in ResMed’s H5i humidifier flip lid.
The company says: “These new devices are designed with the SABIC Lexan and Cycoloy resin materials to be unobtrusive in the home – looking more like a clock radio or stereo than a piece of medical equipment.”
Thursday, November 3rd, 2011 at 10:07 PM
A new classification system detailing the type of signals measured by home sleep testing devices for diagnosing obstructive sleep apnea (OSA) appears in the latest issue of the Journal of Clinical Sleep Medicine.
The proposed system categorizes home sleep testing devices, called out-of-center (OOC) testing devices in the paper, based on measurements of Sleep, Cardiovascular, Oximetry, Position, Effort, and Respiratory (SCOPER) parameters. Criteria for evaluating the devices are also presented, based on pre-test and post-test probabilities.
The first widely used classification system for describing sleep testing devices was published by the American Academy of Sleep Medicine (AASM) in 1994. Read the rest of this entry